143 related articles for article (PubMed ID: 12640983)
41. Gene therapy put on hold as third child develops cancer.
Check E
Nature; 2005 Feb; 433(7026):561. PubMed ID: 15703711
[No Abstract] [Full Text] [Related]
42. Cancer risk prompts US to curb gene therapy.
Check E
Nature; 2003 Mar; 422(6927):7. PubMed ID: 12621402
[No Abstract] [Full Text] [Related]
43. Second cancer case halts gene-therapy trials.
Check E
Nature; 2003 Jan; 421(6921):305. PubMed ID: 12540867
[No Abstract] [Full Text] [Related]
44. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow.
Couzin J; Kaiser J
Science; 2005 Feb; 307(5712):1028. PubMed ID: 15718439
[No Abstract] [Full Text] [Related]
45. Gene therapy: therapeutic gene causing lymphoma.
Woods NB; Bottero V; Schmidt M; von Kalle C; Verma IM
Nature; 2006 Apr; 440(7088):1123. PubMed ID: 16641981
[TBL] [Abstract][Full Text] [Related]
46. The future of gene therapy.
Cavazzana-Calvo M; Thrasher A; Mavilio F
Nature; 2004 Feb; 427(6977):779-81. PubMed ID: 14985734
[No Abstract] [Full Text] [Related]
47. Gene therapy researchers react to field's pitfalls and promises.
Woo SL
FDA Consum; 2000; 34(5):40. PubMed ID: 11590795
[No Abstract] [Full Text] [Related]
48. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
49. US authorities uphold suspension of SCID gene therapy.
Fox JL
Nat Biotechnol; 2003 Mar; 21(3):217. PubMed ID: 12610555
[No Abstract] [Full Text] [Related]
50. [The current status of gene therapy in severe immunodeficiency].
Winckler T
Pharm Unserer Zeit; 2009; 38(3):204-6. PubMed ID: 19396911
[No Abstract] [Full Text] [Related]
51. Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT).
Gansbacher B;
J Gene Med; 2003 Mar; 5(3):261-2. PubMed ID: 12666192
[No Abstract] [Full Text] [Related]
52. Gene therapy.
Heslop HE
Cytotherapy; 2007; 9(6):519-20. PubMed ID: 17882715
[No Abstract] [Full Text] [Related]
53. [Gene therapy of severe combined immunodeficiency disease: proof of principle of efficiency and safety issues. Gene therapy, primary immunodeficiencies, retrovirus, lentivirus, genome].
Fischer A; Hacein-Bey-Abina S; Lagresle C; Garrigue A; Cavazana-Calvo M
Bull Acad Natl Med; 2005 May; 189(5):779-85; discussion 786-8. PubMed ID: 16433450
[TBL] [Abstract][Full Text] [Related]
54. Temporary halt on gene therapy trials.
FDA Consum; 2003; 37(2):6. PubMed ID: 12715756
[No Abstract] [Full Text] [Related]
55. Gene therapy of severe combined immunodeficiencies.
Fischer A; Hacein-Bey S; Cavazzana-Calvo M
Nat Rev Immunol; 2002 Aug; 2(8):615-21. PubMed ID: 12154380
[TBL] [Abstract][Full Text] [Related]
56. A milestone year for gene therapy goes unnoticed.
Günzburg WH
Curr Opin Mol Ther; 2004 Aug; 6(4):358-9. PubMed ID: 15468593
[No Abstract] [Full Text] [Related]
57. Retroviral vectors: new applications for an old tool.
Barquinero J; Eixarch H; Pérez-Melgosa M
Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
[TBL] [Abstract][Full Text] [Related]
58. Gene therapy: shining hopes dented - but not dashed.
Check E
Nature; 2002 Dec 19-26; 420(6917):735. PubMed ID: 12490910
[No Abstract] [Full Text] [Related]
59. [It is no more about cancer, but it is already about gene therapy].
Jeanteur P
Bull Cancer; 2000 Jun; 87(6):445-6. PubMed ID: 10928794
[No Abstract] [Full Text] [Related]
60. Gene therapy for immune disorders: good news tempered by bad news.
Puck JM; Malech HL
J Allergy Clin Immunol; 2006 Apr; 117(4):865-9. PubMed ID: 16630946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
